SREBF1 and metabolic syndrome: As previously reported [12], the alb-SREBP-1a mice developed visceral obesity, fatty liver, and dyslipidemia characterized by increased serum lipids, i.e., triglycerides (TG), but not cholesterol, indicating insulin resistance.